Millions of Americans enrolled in Medicare could face higher prescription drug costs next year following the Trump administration’s announcement to discontinue Biden-era subsidies aimed at reducing premiums. The change affects around 25 million people with stand-alone Part D drug plans under traditional Medicare, who currently pay an average monthly premium of about $36, according to the Kaiser Family Foundation (KFF). Additionally, approximately 31 million beneficiaries receive drug coverage through Medicare Advantage plans, which are offered by private insurers.
Dr. Mehmet Oz, administrator of the Centers for Medicare & Medicaid Services (CMS), addressed the upcoming adjustments via a social media post, stating that most Medicare recipients would see premiums increase by less than $10 and that many may experience lower premiums. However, precise premium costs for 2025 have not yet been announced and will vary depending on the specific plan.
The Biden administration implemented the subsidy program in 2024 to counteract projected significant premium hikes slated for 2025. This initiative provided billions of dollars to insurers with the intent to hold down drug costs for beneficiaries. Republicans criticized the subsidy at the time, arguing it offered only temporary relief and accused the administration of using the program as a political tool ahead of the 2024 elections.
With midterm elections approaching, concerns have been raised about the political and financial impact of higher prescription drug costs, especially as many Americans also face increasing expenses for essentials like food and fuel. Changes in drug plan premiums will become visible to Medicare beneficiaries as they evaluate options for coverage in the upcoming year.
Democratic officials reacted to the Trump administration’s decision, suggesting it will make healthcare less affordable, particularly for seniors. Kendall Witmer, spokeswoman for the Democratic National Committee, stated that the former president and Republicans are “doing everything they can to make health care unaffordable for Americans, especially for seniors.”
The removal of the subsidy raises questions about the balance between government intervention and market-driven pricing in the Medicare drug program and highlights the ongoing political debate over healthcare affordability in the United States.